Attovia Therapeutics' recent upsizing of its IPO to 17 million shares at the $17 high end of the range, pricing on August 4 to raise $289 million with a $731 million post-offering market cap, serves as the primary driver of current Polymarket odds. Strong institutional demand, reflected in the 45% increase in deal size and Goldman Sachs backing, has supported trader expectations for potential first-day trading gains that could push closing market capitalization into the $900 million–$1 billion or higher buckets. As a clinical-stage biotech targeting immune-mediated conditions, the company's positioning against established therapies like Dupixent informs valuation sensitivity to sector multiples and risk appetite. With the offering slated to close August 6 and shares beginning Nasdaq trading under ATTO on August 5, near-term volume and any early price action represent key swing factors for resolution. The low 5% probability assigned to no IPO before October underscores broad consensus that the transaction will complete on schedule.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui<$600M 37%
$900M-$1B 24%
$700M-$800M 23%
$600M-$700M 22%
BARU
BARU
Aug 5, 2026
<$600M
37%
$600M-$700M
22%
$700M-$800M
23%
$800M-$900M
22%
$900M-$1B
24%
$1B+
45%
No IPO before October 2026
10%
<$600M 37%
$900M-$1B 24%
$700M-$800M 23%
$600M-$700M 22%
BARU
BARU
Aug 5, 2026
<$600M
$3 Vol.
37%
$600M-$700M
$0 Vol.
22%
$700M-$800M
$0 Vol.
23%
$800M-$900M
$0 Vol.
22%
$900M-$1B
$0 Vol.
24%
$1B+
$144 Vol.
45%
No IPO before October 2026
$10 Vol.
10%
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics' recent upsizing of its IPO to 17 million shares at the $17 high end of the range, pricing on August 4 to raise $289 million with a $731 million post-offering market cap, serves as the primary driver of current Polymarket odds. Strong institutional demand, reflected in the 45% increase in deal size and Goldman Sachs backing, has supported trader expectations for potential first-day trading gains that could push closing market capitalization into the $900 million–$1 billion or higher buckets. As a clinical-stage biotech targeting immune-mediated conditions, the company's positioning against established therapies like Dupixent informs valuation sensitivity to sector multiples and risk appetite. With the offering slated to close August 6 and shares beginning Nasdaq trading under ATTO on August 5, near-term volume and any early price action represent key swing factors for resolution. The low 5% probability assigned to no IPO before October underscores broad consensus that the transaction will complete on schedule.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Pasar Dibuka: Aug 4, 2026, 9:51 PM ET
Volume
$157Tanggal Berakhir
Aug 5, 2026Pasar Dibuka
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics' recent upsizing of its IPO to 17 million shares at the $17 high end of the range, pricing on August 4 to raise $289 million with a $731 million post-offering market cap, serves as the primary driver of current Polymarket odds. Strong institutional demand, reflected in the 45% increase in deal size and Goldman Sachs backing, has supported trader expectations for potential first-day trading gains that could push closing market capitalization into the $900 million–$1 billion or higher buckets. As a clinical-stage biotech targeting immune-mediated conditions, the company's positioning against established therapies like Dupixent informs valuation sensitivity to sector multiples and risk appetite. With the offering slated to close August 6 and shares beginning Nasdaq trading under ATTO on August 5, near-term volume and any early price action represent key swing factors for resolution. The low 5% probability assigned to no IPO before October underscores broad consensus that the transaction will complete on schedule.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$157Tanggal Berakhir
Aug 5, 2026Pasar Dibuka
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Attovia Therapeutics' recent upsizing of its IPO to 17 million shares at the $17 high end of the range, pricing on August 4 to raise $289 million with a $731 million post-offering market cap, serves as the primary driver of current Polymarket odds. Strong institutional demand, reflected in the 45% increase in deal size and Goldman Sachs backing, has supported trader expectations for potential first-day trading gains that could push closing market capitalization into the $900 million–$1 billion or higher buckets. As a clinical-stage biotech targeting immune-mediated conditions, the company's positioning against established therapies like Dupixent informs valuation sensitivity to sector multiples and risk appetite. With the offering slated to close August 6 and shares beginning Nasdaq trading under ATTO on August 5, near-term volume and any early price action represent key swing factors for resolution. The low 5% probability assigned to no IPO before October underscores broad consensus that the transaction will complete on schedule.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan